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ABSTRACT 
 
 Natamycin (NT), also known as Pimaricin, is predominantly used as an anti-fungal 
medication for the treatment of fungal infections around the eye. The goal of the present study was 
to formulate and optimize NT loaded nanoemulsion (NT-NE) and examine its potential application 
in ophthalmic drug delivery. Placebos were evaluated with respect to particle size, PDI and ZP to 
identify the aqueous phase and lipid phase concentrations to be carried forward with NT-NE 
development. NT-NE were prepared by hot homogenization and ultra-probe sonication method, 
using Castor oil (CO) and Miglyol 812 as liquid lipids, Tween®80 and Poloxomer 188 as 
surfactants. NT-NE were characterized for physicochemical properties such as particle size, 
polydispersity index (PDI), zeta potential (ZP) and assay. The in-vitro release studies were planned 
using 10kDa Slide-A-Lyzer™ Dialysis cassettes and compared with the NT suspension used as 
control (NT-C). Physical stability of NT-NE was measured at room temperature and refrigerated 
storage conditions. Particle size, PDI, ZP of NT-NE were in the range of 150-350 nm, 0.1-0.45 
and -32.0 to -64.73 mV, respectively. The assay of the NT-NE formulations was in the range of 
95-101%. From the release studies, sustained and dose-dependent release of the NT was observed 
from NE compared with NT-C. The approximate %drug release from the castor oil based NT-NE 
(C1) was 15% and 5% from Miglyol 812 NT-NE (M3) in a 24 hour period. The results, therefore, 
suggest that the NT-NE system can be a favorable drug delivery platform for the treatment of 
oculat fungal infections. 
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CHAPTER 1:  INTRODUCTION 
1.1 Advancements in ocular drug delivery systems 
 The field of ocular drug delivery is one of the most interesting, but also most challenging, 
research area for pharmaceutical scientists. The development of new therapeutic compounds 
and novel drug delivery techniques have been constantly evolving for the treatment of ocular 
diseases [1]. Ophthalmic formulations in the current market; like solutions, suspensions, 
implants, ointments and emulsions, have been contributing to the treatment of the ocular 
diseases. The most important diseases which affect the eye globe include diabetic macular 
edema (DME), diabetic retinopathy (DR), macular degeneration (AMD), uveitis, 
fungal/bacterial infections, and glaucoma [2]. These complications could even lead to vision 
loss and other proliferative issues.   
 The need for new ocular drug delivery systems has generated many formulations such as 
bilosomes, nanosuspensions, nanoemulsions, liposomes, microspheres, niosomes, ocular 
films, in-situ gels and many others [1-2]. Many of them are prepared through non-
conventional technologies and sometimes also include nanotechnology systems. These have 
not just have improved the bioavailability of the drug into the eye but also helped in 
overcoming drawbacks like increased precorneal elimination, blurred vision and efficiency.  
1.2 Barriers  
There are certain ocular barriers which need to be outplayed by the formulator without 
causing any ocular tissue injury. Upon topical administration, only 5-10% of the drug reaches 
the site of action and rest of about 90-95% is eliminated by several anatomical factors. These 
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factors are as follows- (i) tear film, (ii) reflexive blinking, (iii) solution overflow, (iv) tear turn 
over, (v) induced lacrimation, (vi) cornea-corneal epithelium controlling the entry of the drug 
molecule into the eye [3]. Also, the mucin present in the tear films, responsible for eliminating 
microorganisms, affects the drug’s ocular penetration [4]. Another factor is the anatomical 
volume of the cul-de-sac (≈30 μl) and the human tear volume (≈7 μl) added to which is the 
rapid elimination (half-life ≈2-3 min), being washed away over the ocular mucosa [2]. Non-
anatomical factor includes patient compliance.  
1.3 Anatomy of the eye  
The anatomy & physiology of the eye is very much invulnerable to foreign particles. The 
eye comprises of two segment - anterior and posterior. The anterior segment of the eye is the 
front third portion of the eye that consists of cornea, iris, ciliary body and lens. The anterior 
cavity further has anterior chamber (the corneal endothelium) and the posterior chamber 
(between iris and vitreous humor). The spaces within the anterior segment is filled by aqueous 
humor; that provides several nutrients to the contiguous structures.  
1.4 Fungal Keratitis  
Fungal keratitis is an infection causing inflammation around the cornea. The current study 
of the thesis offers an idea of developing an ophthalmic formulation to treat fungal infections 
(fungal keratitis) around the eye. Cornea is the outermost, transparent structure present at the 
front of the eye. It covers iris, pupil and anterior chamber which is the eye’s primary light-
focusing structure. The presence of immature resident immune cells, immunologic privilege 
and avascularity property of the cornea makes it a special tissue. The microanatomy of the 
human cornea includes five layers: - (i) corneal epithelium, (ii) Bowman’s layer, (iii) corneal 
stroma, (iv) Descemet’s membrane, (v) Corneal endothelium [5]. Fungal keratitis can develop 
due to eye injury or because of the usage of contact lens. If not treated at an early stage, it can 
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cause permanent vision impairment. There are mostly three fungi that can affect the cornea- 
Fusarium, Aspergillus, or Candida. There can be two types of fungal keratitis intricate- 
superficial keratitis & deep keratitis. As the name suggests, superficial keratitis implicates the 
infection on the outer layers of the corneal tissue whereas deep keratitis affects deeper layers 
of the cornea. It may not avoid the visibility of the scar after getting healed, and mostly cause 
vision loss.  
1.5 Nanoemulsion system 
The anatomical features of cornea which limits the penetration of many lipophilic drugs 
into deeper layers, has created the need to develop better formulations to decrease the problems 
associated with corneal permeation, low bioavailability and low precorneal residence time.  
Solid-lipid nanoparticles (SLN), nanolipid carriers (NLC), polymeric nanoparticles (PN), 
nanocarriers are some of the emerging lipid/polymeric nano-formulations which have shown 
success in augmenting the transcorneal drug permeability [9, 10]. Currently, to treat fungal 
keratitis, the only available ophthalmic product available commercially is NatacynVR (NT 5% 
w/v suspension). This suspension contains Natamycin drug, which is a macrolide polyene 
antifungal agent. US-FDA has approved this NT based suspension commercially for the 
treatment of fungal keratitis and several other fungal infections [7, 8]. The available therapy 
needs multiple dosing (a drop every 1-2 h) for several weeks to attain the ideal concentrations 
at the corneal site [9, 10]. This is because of the low aqueous solubility at the corneal site. 
Therefore, there is a need to develop a formulation to improve corneal permeability and 
bioavailability of NT so as to reduce the multiple dosing rate and increase the efficacy, patient 
compliance through the nano-technique based formulation.  
Nanoemulsions are defined as colloidal dispersions wherein two immiscible liquids are 
mixed with the effect of external forces or energies. There are certain advantages of utilizing 
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nanoemulsions over conventional emulsions in the current pharmaceutical industry.  The two 
immiscible liquids involve oil and water. Thus, it can be classified into two types- (O/W) and 
(W/O). The structural characteristics of nanoemulsion was suitably chosen with the idea that 
the small size of the droplets often leads to a higher bioavailability of the bioactive components. 
The encapsulated bioactive compound creates an increased equilibrium solubility with the 
decreased size of the droplets further leading to an enhanced concentration gradient for 
absorption [11]. Previously, PEGylated nanostructured lipid carriers, in situ gels of bilosomes 
and transfersomes of NT were reported but no NE formulations have been reported so far [6, 
12]. 
The current investigation mainly focused on NT-loaded nanoemulsion (NT-NE) for 
improved ocular pharmacotherapy based on the (O/W) nanoemulsion formulations since NT 
is a highly lipophilic drug. Accordingly, NT-NE were prepared using homogenization followed 
by probe sonication method and evaluated for particle size, PDI, ZP and drug content. Further, 
in vitro release studies of an optimized NT-NE were performed, compared with NT control 
suspension (0.3% NT w/v).  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Materials 
Castor oil (CO) (ricinoleic acid) and egg lecithin (phospholipid) were purchased from 
Fischer Scientific. NT was purchased from Cayman Chemicals (Ann Arbor, MI, USA). 
Poloxamer 188, Tween® 80, centrifugal tubes, high-performance liquid chromatography 
(HPLC)-grade solvents, and other analytical-grade chemicals were purchased from Fisher 
Scientific (Hampton, NH, USA). Dialysis membrane cassettes (molecular weight cut off 10K) 
were purchased from Fischer Scientific. 
2.2 Methods 
2.2.1 Preparation of NT-NE placebos 
Different trials were used to develop nanoemulsions with the change in surfactants and 
their concentrations, different oils and change in homogenization parameters.  
2.2.1.1 Assessment of surfactants  
   Surfactants are the compounds which are used at variable concentrations as emulsifiers. 
For the preparation of nanoemulsion in the current research, use of nonionic surfactants were 
chosen due to its high effectiveness, efficiency, biodegradability and low toxicity concerns. 
The formulations trials were carried with Poloxomer 188, tyloxopol, chremophor el, and 
Tween® 80. Variable compositions made are listed in Table 1 below. 
2.2.1.2 Assessment of oil 
Natamycin is from the polyene family of medication which is highly lipophilic in nature. 
The trials were carried out with oil and liquid lipid fatty acid. Screening of different oils were 
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carried in previous literature reports [12]. The reported results were in favor of castor oil. 
Furthermore, Miglyol 812 (fatty acid) were also tried as per many reported stable concerns in 
previous literature. Reference to Table 1 & Table 2.   
 P1 P2 P3  P4 P5 P6 P7 P8 P9 P10 
Natamycin -- -- -- -- -- --     
Castor oil 1% 2% 3% 1% 1% 1% 1% 1% 2% 2% 
Miglyol 812 -- -- -- -- -- --     
Egg Lecithin -- -- -- -- -- --     
Poloxomer ® 
188 0.25% 0.25% 0.25% -- -- 0.25% 0.25% 0.25% 0.25% 0.25% 
Tween ® 80 0.75% 0.75% 0.75% 0.50% 0.75% 0.75% 1% 2% 1% 2% 
Tyloxopol -- -- -- -- -- 0.20%     
TPGS vit. E -- -- -- -- --      
Chremophor 
EL -- -- -- 0.25% 0.50% --     
Glycerin 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 2.25% 
Water 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
upto 
10ml 
Table 1: Composition of nanoemulsion placebos 
 
2.2.2 Preparation of NT-NE 
 After several placebos trials, NT-NE were prepared by using hot homogenization followed by 
ultra-probe sonication method as per the composition given in Table 2. The oil phase with a 
combination of oil and egg lecithin (0.5% w/v) was heated to 80 ± 2°C and NT was added with 
continuous stirring. Simultaneously, the aqueous phase consisting of Tween® 80 (0.75% w/v) 
and Poloxomer 188 (0.25% w/v) in de-ionized water (upto 10 ml) was heated at same 
temperature. Aqueous phase then transferred to the molten oil mixture under constant stirring 
at 2000 rpm. A pre-mixture was then obtained by emulsification process, using a T25 digital 
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Ultra-Turrax (IKA, Wilmington, NC, USA) for 5 min set at 16000 rpm. Pre-emulsion was then 
subjected to probe sonication at 40% amplitude for 10 mins with 10 sec pulse on and 15 sec 
pulse off, using Sonics Vibra Cell Sonicator (Newtown, Connecticut, USA). Compositions are 
presented in Table 2. 
Table 2. Composition of natamycin loaded nanoemulsion with different compositions 
selected. 
 
 M1 M2 M3 M4 C1 
Natamycin 1% 2% 1% 2% 0.3% 
MIGLYOL 812 3% 3% 5% 5% -- 
CASTOR OIL -- -- -- -- 1% 
Egg Lecithin 0.5% 0.5% 0.5% 0.5% 0.5% 
     Poloxomer ® 188 0.25% 0.25% 0.25% 0.25% 0.25% 
Tween ® 80 0.75% 0.75% 0.75% 0.75% 0.75% 
Water      Upto 10 ml     Upto 10 ml Upto 
10 ml 
Upto 
10 ml 
    Upto 10 ml 
 
 
 
2.2.3. Measurement of Particle size, Zeta Potential and Polydispersity Index 
  The particle size, zeta potential (ZP) and polydispersity index (PDI) of the placebos and 
NT-NE prepared were determined by using a Zetasizer Nano ZS Zen3600 (Malvern 
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Instruments, Westborough, MA, USA); a photon correlation spectroscopy device; at 25 °C in 
clear, disposable folded capillary cells. The measurements were attained using a helium-neon 
laser based on which the data was analyzed as per the volume distribution. Ten microliters of 
sample were diluted 100 times with filtered bi-distilled, 0.2 micron filtered water and measured 
for particle size and zeta potential in triplicate. 
 
2.2.4. Chromatographic Conditions for Sample Analysis 
 Drug content (Assay) and in-vitro release study samples were analyzed using high performance 
liquid chromatography (HPLC) method [12]. The HPLC which was used for the analysis 
constitutes Waters 717 plus auto sampler, Waters 2487 dual absorbance UV detector, 600 
Waters controller pump, and an Agilent 3395 Integrator. A C18 Phenomenex Luna® (5µ, 250 
x 4.6 mm) column was used. The mobile phase contained a mixture of phosphate buffer (0.2M, 
pH 5.5) and acetonitrile (70:30) at a flow rate of 1 ml/min. The analysis was done under 25 °C, 
injection volume was 20 µL, and the UV detection wavelength (λmax) was set to 304 nm at 
AUFS 1.00.  
 
2.2.5. Drug content (Assay) of NT-NE  
An accurately measured amount of NT-NE (100 µL) was extracted in methanol (filled upto 
meniscus) in a 10 mL volumetric flask. The mixture was sonicated for 15 min at 15 °C. It was 
then centrifuged at high speed (13,000 rpm; 10 min; 25 °C) and the supernatant was analyzed 
for NT content using HPLC.    
 
2.2.6. Physio-chemical stability assessment  
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The NT-NE formulations were assessed by analyzing physical appearance, change in 
particle size, PDI, ZP and assay upon storage at 4 °C and 25 °C for a period of one month.  
 
2.2.6. In vitro release studies 
  In vitro release of NT-NE were carried out for 24 hours using 10K dialysis membrane. 
Prior to the study, cassettes were soaked in de-ionized water overnight at room temperature. 
The membrane cassettes were carefully placed upon scintillation vials containing isotonic 
phosphate buffer (IPBS) (20 mL; pH=7.4) which were kept on multi-stationed magnetic stirrer 
(IKA, USA) at 1000 rpm at static conditions. The temperature was maintained at 34 °C 
throughout the study. To keep a check, the probe was positioned in another scintillation vial 
containing same 20 mL (IPBS) without the membrane cassette placed on the device. Freshly 
prepared NT-NE were prepared for the in vitro studies. NT-C was prepared by adding 0.05% 
sodium carboxymethyl cellulose (NaCMC) to 0.3% NT in a 20 mL scintillation vial and 
triturated with addition of half quantity of 0.2 micron Millipore water (upto 10 mL).  Two 
hundred microliter of NT-NE and NT-C formulations were put into the membrane cassettes in 
triplicate. Further at proper time interval, 1 mL of release medium was taken and fresh IPBS 
was added to maintain the persistent volume of the system. The drug release of NT was 
analyzed using HPLC as per the above described method. 
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CHAPTER 3: RESULTS & DISCUSSION 
 
3.1 Assessment of placebos  
 The placebos made with variant concentrations of non-ionic surfactants and oil differed in 
either size, PDI or ZP. Also, settling of particles at the bottom of the vial was visually 
evaluated. P3, P4, P5, P6 & P8 exhibited settling of particles at the bottom mostly within 2-3 
days.  
Table 3: Particle size, PDI, ZP of NE (mean ± SD, n = 3). Refer to Table 1 for NT-NE 
compositions. 
Formulation Size (nm) PDI ZP (mV) 
P1 104.1 ± 2.15 0.27 ± 0.004 -27.2 ± 2.79 
P2 339.73 ± 36.8 0.72 ± 0.06 -30.4 ± 0.15 
P3 322 ± 5.23 0.46 ± 0.05 -40.1 ± 0.05 
P4 5.02E 0.3 ± 0.19 -63.2 ± 0.12 
P5 925 ± 194.0 0.96 ± 0.05 -61.5 ± 0.18 
P6 1.01E 0.3 ± 0.19 -60.1 ± 0.81 
P7 290.4 ± 56.1 0.45 ± 0.01 -41.3 ± 1.9 
P8 841.8 ± 151.0 0.75 ± 0.06 -37.1 ± 0.67 
P9 370 ± 146.0 0.70 ± 0.17 -42.2 ± 0.28 
P10 336 ± 78.40 0.58 ± 0.21 -33.2 ± 0.43 
 
3.2 Assessment of NT-NE 
3.2.1. Choice of lipid phase  
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For further development, the lipid phase was chosen to be formulated in oil (CO) and a 
fatty acid (Miglyol 812) for NE to compare the results based on size, PDI, ZP and drug content. 
As per the literature, it was reported that on screening solubility of NT with different oils and 
liquid lipids; castor oil (CO) had showed best solubility when used in oil phase [12]. Miglyol 
812 also showed better solubility of NT.  Therefore, NT-NE formulations were prepared with 
varied concentrations of CO (oil) and Miglyol 812 (fatty acid) with NT in the oil phase. 
Aqueous phase constituting of Tween® 80 and Poloxomer 188 were optimized based on 
placebos and were kept same in all the formulations. The percent content for all the excipient 
were as per the limit mentioned in the inactive ingredients (IIG) database [13].  
NT-NE formulations were prepared using homogenization followed by probe sonication 
method. To develop the NE, varied concentrations of liquid lipids v/s NT ratios were studied 
on the basis of particle size and PDI. The compositions are listed in the Table 2. It was observed 
that, when the oil ratio (Miglyol 812) was kept constant in M1 and M2 at 3%, and NT 
concentration was increased from 1% (M1) to 2% (M2) showed particle size and PDI of 210.2 
± 2.93 and 0.41 ± 0.07 in M1, which is less than the particle size and PDI of 292.6 ± 1.9 and 
0.58 ± 0.069 in M2 (Table 2). The increase in particle size is due to the increase in drug load 
and the increase in PDI could be due to the amount of surfactants ratio are not been sufficient 
to stabilize the nanoemulsion system.  
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Table 4: Particle size, PDI, ZP and drug content of NT-NE (mean ± SD, n = 3) 
     
Formulation Size (nm) PDI ZP (mV) Assay (%) 
M1 
210.2 ± 2.93 
 
0.41 ± 0.07 
 
-41.06 ± 6.61 
 
79.6 ± 0.55 
 
M2 292.6± 1.9 
0.58± 0.069 
 
-43.3±3.21 
 
55.8± 0.07 
M3 
179.2 ± 0.6 
 
0.29 ± 0.03 
 
-46.1 ± 2.4 
 
97.5 ± 1.9 
M4 
256.8± 68.8 
 
0.37 ± 0.01 
 
-57.2 ± 1.5 
 
38.7 ± 0.08 
 
C1 
212.7 ± 6.7 
 
0.46 ± 0.04 
 
-66.1±0.3 
 
101.2±0.06 
 
 
On increasing the oil content of Miglyol 812 in M3 & M4 at 5% concentrations and varied 
NT content of 1% and 2% drug load, there was a higher particle size in M4 (256.86 ± 68.82) 
with higher PDI (0.37 ± 0.011) as compared to particle size in M3 (179.2 ± 0.66) and PDI (0.29 
± 0.035). The increase in particle size of M4 could be because of the higher drug load amount 
(NT) not been encapsulated appropriately in the lipid concentration of 5%.  
In C1, where the castor oil is being replaced by the Miglyol 812 at 1% concentration with 
0.3% NT, showed particle size of 212.7 ± 6.7 and PDI of 0.46 ± 0.04. It has been suggested 
that PDI values differing in the range of 0.01 to 0.5 represents narrow distribution range [14]. 
From the results, M1, M3, M4 and C1 falls under the reasonable PDI range. But, M4 constitutes 
of higher particle size value, this was not considered as a desired NE system.  
 ZP of NT-NE ranged from -57.2 ± 1.5 to -41.0 ± 6.6 mV for Miglyol 812 based nanoemulsions 
and -66.1 ± 0.3 that of castor oil based NE. The stability of the NE system also depends upon 
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the steric stabilization of the formulations. The non-ionic surfactant (Poloxomer 188) used in 
the nanoparticulate system helps in reducing the electrostatic repulsion between the particles 
following stabilization when introduced to the corneal site. A lower zeta potential system 
between (-30 mV) to (+30 mV) is considered to have a better steric stability of the 
nanoemulsion system [6].  
 
3.3 Drug content 
The amount of NT loaded in the oil or lipid matrix depends upon the type of oil used [15]. 
Here, NE developed with castor oil and miglyol 812. The solubility of NT differs in both the 
oil & lipid matrix system, respectively. Considering the results in Table 4, the drug content in 
M3 (97.5 ± 1.9%) and C1 (101.2 ± 0.06%) were higher as compared to other NT-NE 
formulations. Moreover, the solubility of the NT with the lipids and oils depends upon the 
crystalline structural imperfections in the oil/lipid matrix system. Higher the structural 
imperfections, higher would be the solubility since it contains higher void spaces in between 
them. Also, castor oil containing hydroxyl functional group (-OH) is more polar than several 
other fatty acids. Higher the polarity, higher will be solubility of the drug compound. Thus, we 
can also conclude that NT being highly lipophilic in nature is more soluble in castor oil than 
Miglyol 812 which is why higher concentration of Miglyol 812 was required to dissolve higher 
drug load.   
 
3.4. Stability studies  
The NT-NE formulations (M3 and C1) selected were further analyzed for stability at 
refrigerator and room temperatures. The stability results are presented in Table 5 and Table 6. 
From the Table 5, it is appatent that there was no significant difference among particle size and 
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PDI from Day 1 to Week 3 in M3 NE. On the contrary, a significant difference in drug contents 
were observed from Day 1 until week 2.  
For the C1 nanoemulsion formulation (Table 6), it was observed that there is a decrease in 
particle size at both temperatures and no particular difference was observed regarding PDI. 
The zeta potential for this nanoemulsion system remained same until week 2. The assay did 
not show much difference for the NT-NE kept in 4 °C but lowered by about 10-12% at 25 °C. 
Table 5. Stability studies of NT-NE formulation (M3) at refrigerator and room temperature for 
one month (mean ± SD, n = 3). Refer to Table 2 for NT-NE compositions. 
Duration Condition Size (nm) PDI Zeta Potential  
Assay 
(%) 
Day 1 
4 °C 179.2 ± 0.6 0.29± .03 -46.1 ± 2.4 97.5 ± 1.9 
25 °C 170.8 ± 2.1 0.28±0.005 -50.8± 0.4 95 ± 0.2 
Week 2 
4 °C 191.3 ± 2.45 0.30 ± 0.03 -46.1 ± 2.45 81.5 ± 0.4 
25 °C 162.2 ± 1.41 0.17 ± 0.02 -56 ± 3.81 81.3 ± 0.4 
 
 
 
Table 6. Stability studies of NT-NE formulation (C1) at refrigerator and room temperature 
for one month (mean ± SD, n = 3). Refer to Table 2 for NT-NE compositions. 
 
Duration 
Conditio
n Size (nm) PDI Zeta Potential Assay (%) 
Day 1 4 °C 212.7 ± 6.7 0.46 ± 0.04 -66.1 ± 0.3  101.2 ± 0.06 
 25 °C 247.7 ± 10.1 0.44 ± 0.04 -64.7 ± 0.6  99.4 ± 0.3 
Week 2 4 °C 204.8 ± 36.4 0.418 ± 0.02 -66.3 ± 1.8 93.8 ± 0.04 
 25 °C 277.9 ± 136.1 0.505 ± 0.07 -62.8 ± 1.6 86.5± 0.02 
 
3.5. In vitro release study 
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The in-vitro release studies were carried for both M3 & C1 for 24 hours. For M3 
nanoemulsion formulation, the drug release at 24th hour was about 4.86% and that of C1, it 
was observed to be 14.3%. The control (0.3% w/v NT; 0.5% Sodium CMC; 10 ml water) was 
observed to have 80.38% of average release at 24th hour.  
This suggests that with increase in drug load, there is an increment of sustain release 
actions. The average frequency of application of the marketed Natamycin suspension 
(NatacynVR) is usually between 6 to 8 times daily. But with the developed NT nanoemulsion 
system, the dosing frequency could be reduced to once in a day thus reducing toxic effects, 
and increasing patient compliance as well. Table 7 represents the 24-hour study data for both 
the formulations developed. 
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Table 7: In vitro release profiles of NT-NE (M3 and C1) and NT-C formulations (mean 
± SD, n = 3). Refer to Table 2 for NT-NE compositions. (NT-C: 0.3% w/v NT + 0.5% 
Sodium CMC + 10 ml water) 
  
Time (hrs.) 
C1 M3 NT-C 
%drug release %drug release %drug release 
0.5 0.85 ± 0.05 0.24 ± 0.008 1.65 ± 0.09 
1 1.14 ± 0.13 0.33 ± 0.01 2.59 ± 0.18 
2 1.84 ± 0.11 0.54 ± 0.03 4.79 ± 0.50 
4 2.99 ± 0.14 0.94 ± 0.08 9.86 ± 1.15 
6 4.32 ± 0.29 1.32 ± 0.08 17.98 ± 0.43 
8 5.36 ± 0.26 1.69 ± 0.07 21.28 ± 2.37 
12 7.73 ± 0.41 2.55 ± 0.14 34.12 ± 3.60 
24 14.30 ± 0.92 4.86 ± 0.43 80.78 ± 7.49 
 
                 
 
Figure 1: In vitro release profiles NT from NT-NE (M3 and C1) and NT-C formulations 
(mean ±SD, n = 3). Refer to Table 7 for values. 
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CHAPTER 5: CONCLUSION 
 
NT loaded nanoemulsion with liquid lipid Miglyol 812 and castor oil (CO) were 
successfully developed and optimized. NT-NE with castor oil at 4 ºC showed small particle size 
with narrow particle distribution for upto 2 weeks. The drug content did not show much of the 
difference. Although, NT with Miglyol 812 showed stable particle size, PDI and ZP for upto two 
weeks, drug content decreased. The in vitro release study revealed the sustained release and dose-
dependent effect of NT-NE compared with NT control formulation. Future studies require to study 
stability of the formulations for a longer duration of time to confirm the effectiveness of the 
formulation with its stability. Also, transcorneal permeation and in-vivo ocular distribution studies 
could confirm the efficacy and residence time of NT-NE on the ocular surface. 
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